Crown Bioscience Inc.
CrownBio Enters Strategic Partnership with Phanes Therapeutics to Accelerate Discovery and Development of Phanes' Novel Oncology Agents
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.
CrownBio provides the world's largest collection of Patient-Derived Xenograft (PDX) models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments. Phanes will gain access to CrownBio's clinically relevant CDX models, exclusive PDX models and robust in vitro assays to propel their innovative drug discovery pipeline.
Dr. Ming Wang, President and CEO of Phanes Therapeutics, expressed enthusiasm about this partnership, "We are an innovative drug discovery company with a robust pipeline and need access to top notch in vivo pharmacology efficacy models to quickly evaluate and advance our lead molecules. We are very glad to partner with CrownBio. They have very unique MuPrime(TM) models, as well as Humanized GEMMs (HuGEMM(TM)) and Patient-Derived Xenograft (PDX) models for our oncology programs. We look forward to a productive partnership."
"We are very pleased that Phanes Therapeutics has selected us as a trusted partner to advance their leading-edge oncology compounds," said Laurie Heilmann, CrownBio's Chief Business Officer. "Our unique capabilities will help Phanes efficiently and thoroughly assess drugs in their pipeline to identify and advance candidates showing the most promise for improved treatment of cancer."
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
About Phanes Therapeutics
Phanes Therapeutics is a biotech company with strong innovative drug discovery and development programs in metabolic complications and oncology areas. It was founded by former Janssen/J&J Vice President Ming Wang, PhD, MBA. The company focuses exclusively on biologics drug discovery with multiple first-in-class and best-in-class molecules in its pipeline. For more information on Phanes, please visit www.phanesthera.com.
Crown Bioscience Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
VistaJet Ltd19.2.2019 11:35:28 | Pressemeddelelse
VistaJet Partners With Scuderia Ferrari Mission Winnow for the 2019 Formula One World Championship
Association of Corporate Counsel19.2.2019 11:01:16 | Pressemeddelelse
ACC Opens New Europe Headquarters in Brussels
Centrient Pharmaceuticals19.2.2019 09:01:40 | Pressemeddelelse
The Delhi High Court in India has issued an injunction, restraining Sinopharm Weiqida from exporting its “Amoxycillin Trihydrate” product to India, as it infringes the patent of Centrient Pharmaceuticals
Cansativa GmbH19.2.2019 07:16:08 | Pressemeddelelse
New Milestone for Cansativa Towards “EU GxP Innovation Hub”
Juniper Systems Limited19.2.2019 05:17:30 | Pressemeddelelse
Juniper Systems Limited Launches New Cedar CT8 Rugged Tablet
INVNT18.2.2019 23:39:50 | Pressemeddelelse
INVNT No Longer Involved, As Bethel Woods Music and Culture Festival Changes Direction and Becomes Three Separate Events
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum